MARKET

AGTC

AGTC

AGTC
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.300
-0.130
-3.79%
After Hours: 3.300 0 0.00% 17:00 09/20 EDT
OPEN
3.340
PREV CLOSE
3.430
HIGH
3.430
LOW
3.260
VOLUME
464.77K
TURNOVER
--
52 WEEK HIGH
9.67
52 WEEK LOW
3.120
MARKET CAP
141.09M
P/E (TTM)
-1.5272
1D
5D
1M
3M
1Y
5Y
AGTC to Host Fourth Quarter and 2021 Fiscal Year End Financial Results Conference Call and Webcast on September 23, 2021
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases (IRDs), today announced that it will...
GlobeNewswire · 4d ago
Notable earnings before Tuesday's open
AGTC, FCEL For Seeking Alpha's full earnings season calendar, click here.
Seekingalpha · 09/13 14:39
AGTC to Participate in Clinical Trials in Rare Diseases Conference Panel and Case Study
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases (IRDs), today announced that Jill Do...
GlobeNewswire · 09/09 12:00
AGTC to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that management will be participating...
GlobeNewswire · 09/07 14:23
AGTC to Present at the 2021 Wells Fargo Virtual Healthcare Conference
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatm...
GlobeNewswire · 09/02 13:41
Knoll Capital Management, LLC Buys Entera Bio, Annovis Bio Inc, Advanced Micro Devices Inc
GuruFocus News · 08/24 17:38
Greater Gift, AGTC, and 2020 On-site Partner To Honor & Celebrate Clinical Trial Participants and Provide Eye Exams to Underserved Children in the Local Community
Greater Gift of Winston Salem, a non-profit that celebrates participation in clinical trials today announced a partnership with Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company developing genetic therapies for the treatment ...
GlobeNewswire · 08/24 12:00
AGTC Announces Sponsorship of Achroma Corp’s No Roadblocks Program
-Program helps those living with Achromatopsia receive filtered glasses and contact lenses to qualify for bioptic driving- GAINESVILLE, Fla., and CAMBRIDGE, Mass., Aug. 19, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a...
GlobeNewswire · 08/19 20:05
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AGTC. Analyze the recent business situations of AGTC through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AGTC stock price target is 15.78 with a high estimate of 35.00 and a low estimate of 8.00.
EPS
Institutional Holdings
Institutions: 100
Institutional Holdings: 15.05M
% Owned: 35.20%
Shares Outstanding: 42.75M
TypeInstitutionsShares
Increased
13
1.44M
New
13
728.53K
Decreased
31
4.85M
Sold Out
24
1.95M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.58%
Pharmaceuticals & Medical Research
-1.08%
Key Executives
Chairman/Independent Director
Scott Koenig
President/Chief Executive Officer/Director
Susan Washer
Executive Vice President
Matthew Feinsod
Chief Accounting Officer/Treasurer
Jerry Reynolds
Vice President
Stephen Potter
Director
Yehia Hashad
Independent Director
William Aliski
Independent Director
Edward Hurwitz
Independent Director
Ivana Magovcevic-Liebisch
Independent Director
James Rosen
Independent Director
Anne Vanlent
No Data
  • All
  • Financials
  • Insiders
More
About AGTC
Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company uses gene therapy platform to develop genetic therapies for patients suffering from rare and debilitating diseases. Its focus is in the field of ophthalmology where it has active clinical programs in X-linked retinitis pigmentosa (XLRP), achromatopsia (ACHM), and optogenetics. The Company has approximately one preclinical program in otology and three preclinical programs targeting central nervous system disorders (CN), including adrenoleukodystrophy (ALD), frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The Company's optogenetics program is being developed in collaboration with Bionic Sight, LLC and its otology program is being developed in collaboration with Otonomy, Inc. In addition to its product pipeline, the Company has also developed broad technological and manufacturing capabilities in synthetic promoter development and optimization.

Webull offers kinds of Applied Genetic Technologies Corp stock information, including NASDAQ:AGTC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AGTC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AGTC stock methods without spending real money on the virtual paper trading platform.